Biotech Giant Amgen Wins Another Patent for EPO
- Share via
Amgen Inc., the Thousand Oaks-based biotechnology giant, has been issued another patent by the U.S. Patent and Trademark Office related to the manufacture of its red blood cell drug erythropoietin.
EPO was Amgen’s first drug, approved for sale by the FDA in 1989. It has become a blockbuster, used to treat anemia in patients with kidney disease.
In the past Amgen has fought and won protracted legal battles with rivals to protects its EPO patents.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
